Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older
- PMID: 31895431
- PMCID: PMC7329570
- DOI: 10.1001/jamacardio.2019.5200
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older
Conflict of interest statement
Comment in
-
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.JAMA Cardiol. 2020 Feb 1;5(2):235-236. doi: 10.1001/jamacardio.2019.5241. JAMA Cardiol. 2020. PMID: 31895449 No abstract available.
Comment on
-
Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiol. 2019 Sep 1;4(9):846-854. doi: 10.1001/jamacardio.2019.2306. JAMA Cardiol. 2019. PMID: 31314050 Free PMC article. Clinical Trial.
References
-
- Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2019;4(9):846–854. doi:10.1001/jamacardio.2019.2306 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources